PURPOSE: To report on the aggressiveness of sporadic versus familial prostate cancer. PATIENTS AND METHODS: The study sample consisted of 4,112 stage T1-3 prostate cancer patients. The outcome of interest was biochemical relapse-free survival (bRFS). The analysis was performed for two distinct time periods, 1986 to 1992 (year < or = 1992) and 1993 to 2002 (year > or = 1993), to encompass both the early and late prostate-specific antigen (PSA) eras. RESULTS: A positive family history (FH positive) was reported in 16%. The 10-year bRFS rates for patients with negative family history (FH negative) versus FH positive were 59% and 63%, respectively (P = .90). However, in the year < or = 1992 period, the 10-year bRFS rates for FH negative versus FH positive were 45% and 34%, respectively (P = .015). In the year > or = 1993 period, the 10-year bRFS rates for FH negative versus FH positive were 61% and 67%, respectively (P = .54). Multivariate analysis failed to reveal family history as an independent predictor of relapse (P = .42). However, in the subset of patients in each era, family history was an independent predictor of relapse only for those treated in the year < or = 1992 period (P = .038). CONCLUSION: Family history was an independent predictor of biochemical failure only early in the PSA era, and men with an FH positive presented with more favorable disease later in the PSA era. This suggests that with stage migration and improved therapy, the impact of family history on prognosis has become minimal. However, underlying genetic factors affecting prostate cancer behavior in individuals with familial prostate cancer may still be important in determining individual prognosis.
PURPOSE: To report on the aggressiveness of sporadic versus familial prostate cancer. PATIENTS AND METHODS: The study sample consisted of 4,112 stage T1-3 prostate cancerpatients. The outcome of interest was biochemical relapse-free survival (bRFS). The analysis was performed for two distinct time periods, 1986 to 1992 (year < or = 1992) and 1993 to 2002 (year > or = 1993), to encompass both the early and late prostate-specific antigen (PSA) eras. RESULTS: A positive family history (FH positive) was reported in 16%. The 10-year bRFS rates for patients with negative family history (FH negative) versus FH positive were 59% and 63%, respectively (P = .90). However, in the year < or = 1992 period, the 10-year bRFS rates for FH negative versus FH positive were 45% and 34%, respectively (P = .015). In the year > or = 1993 period, the 10-year bRFS rates for FH negative versus FH positive were 61% and 67%, respectively (P = .54). Multivariate analysis failed to reveal family history as an independent predictor of relapse (P = .42). However, in the subset of patients in each era, family history was an independent predictor of relapse only for those treated in the year < or = 1992 period (P = .038). CONCLUSION: Family history was an independent predictor of biochemical failure only early in the PSA era, and men with an FH positive presented with more favorable disease later in the PSA era. This suggests that with stage migration and improved therapy, the impact of family history on prognosis has become minimal. However, underlying genetic factors affecting prostate cancer behavior in individuals with familial prostate cancer may still be important in determining individual prognosis.
Authors: Hilary Bagshaw; Karen Ruth; Eric M Horwitz; David Y T Chen; Mark K Buyyounouski Journal: Radiother Oncol Date: 2014-02-20 Impact factor: 6.280
Authors: Sung Kyu Hong; Jung Soo Nam; Woong Na; Jong Jin Oh; Cheol Yong Yoon; Chang Wook Jeong; Hyun June Kim; Seok-Soo Byun; Sang Eun Lee Journal: Asian J Androl Date: 2011-06-27 Impact factor: 3.285
Authors: Andreas Dinkel; Marielouise Kornmayer; Jürgen E Gschwend; Birgitt Marten-Mittag; Peter Herschbach; Kathleen Herkommer Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375
Authors: Mark Thalgott; Martina Kron; Johannes M Brath; Donna P Ankerst; Ian M Thompson; Juergen E Gschwend; Kathleen Herkommer Journal: World J Urol Date: 2017-11-21 Impact factor: 4.226
Authors: Marco Randazzo; Alexander Müller; Sigrid Carlsson; Daniel Eberli; Andreas Huber; Rainer Grobholz; Lukas Manka; Ashkan Mortezavi; Tullio Sulser; Franz Recker; Maciej Kwiatkowski Journal: BJU Int Date: 2015-10-06 Impact factor: 5.588
Authors: Ruben Cremers; Christi van Asperen; Paul Kil; Hans Vasen; Tjerk Wiersma; Inge van Oort; Lambertus Kiemeney Journal: Fam Cancer Date: 2012-06 Impact factor: 2.375